YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

KaloBios stock soars after investment from infamous drug CEO

Posted online
Shares of cancer drug developer KaloBios Pharmaceuticals are skyrocketing after Martin Shkreli, the infamous CEO behind Turing Pharmaceuticals, took a majority stake in the company.

After KaloBios disclosed an investor group led by Shkreli acquired most of its stock, shares surged to as high as $11.87 after closing Wednesday at $2.07.

The former hedge fund manager came under fire in September when his company raised the price of parasitic infection drug Daraprim by over 5,000 percent.

Read more from The Associated Press.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences